Baxter International’s Earnings Call Signals Cautious Turnaround

Baxter International Inc ((BAX)) has held its Q1 earnings call. Read on for the main highlights of the call.

Baxter International’s latest earnings call struck a cautiously optimistic tone, as management highlighted operational gains and a clearer turnaround roadmap while confronting a steep earnings drop and margin pressure. Executives leaned on improving cash flow, product launches, and efficiency programs to argue for a second-half recovery, but near-term headwinds in margins and supply chains kept enthusiasm in check.

Solid Top Line but Weak Organic Performance

Global sales from continuing operations reached $2.7 billion, up 3% year over year on a reported basis, showing some resilience despite a tough backdrop. However, organic sales slipped 1%, underscoring that underlying demand remains soft and that reported growth was largely aided by foreign exchange rather than volume strength.

Free Cash Flow Swings Back to Positive

First-quarter free cash flow improved sharply to $76 million from negative $221 million in the prior year period, signaling better cash discipline. Management credited stronger cash generation and more efficient working capital management, a critical step as Baxter prioritizes debt reduction and balance sheet repair.

Advanced Surgery Leads with Double-Digit Growth

Advanced Surgery stood out as a bright spot, delivering $304 million in sales, up 10% year over year and outpacing the broader portfolio. Growth was driven by solid demand for hemostats and sealants and stable procedural volumes, reinforcing this segment as a key earnings lever in an otherwise pressured portfolio.

Drug Compounding Delivers High Growth

Drug compounding posted roughly 20% growth, fueling momentum in the Pharmaceuticals segment and reflecting robust demand for outsourced compounding services. This high-growth niche provides Baxter with a valuable counterbalance to weaker areas, particularly as the company navigates broader pharmaceutical supply challenges.

New Products Showcase Innovation Push

Baxter highlighted a wave of product launches, including the Dynamo smart hospital stretcher, the IV Verified Line labeling system, an XR spine surgical table, and the Connex 360 platform. The company is also embedding AI into its Connected Care Foundation and frontline workflows, aiming to deepen hospital integration and strengthen its long-term competitive moat.

Continuous Improvement Program Scales Up

Operationally, the Baxter GPS continuous improvement program gained traction with 10 President Kaizen events and more than 230 improvement initiatives underway. Management is also delayering the organization and pushing P&L accountability to operating leaders, a move intended to speed decisions and sharpen cost discipline across the business.

Backorder Clearance Supports Pharma Stability

The company reported notable progress in clearing backorders at a key manufacturing site, improving throughput and supporting a more stable supply outlook for its Pharma business. This remediation is critical for rebuilding customer confidence and should reduce the operational noise that has weighed on service levels and revenue.

Financial Framework Reaffirmed Despite Headwinds

Despite soft first-quarter trends, Baxter reaffirmed its full-year 2026 framework, calling for reported sales growth of flat to up 1% and roughly flat organic revenue. The company maintained its adjusted operating margin target of 13%–14% and adjusted EPS range of $1.85–$2.05 from continuing operations, underscoring management’s confidence in a back-half-driven recovery.

Debt Reduction Leads Capital Allocation Priorities

With free cash flow turning positive, Baxter reiterated that deleveraging remains its top capital allocation priority, targeting net leverage of about 3x by the end of 2026. Only after achieving this leverage goal does management plan to consider tuck-in acquisitions or share repurchases, suggesting a disciplined, balance-sheet-first posture.

Earnings Drop Underscores Turnaround Challenge

Adjusted earnings from continuing operations fell to $0.36 per diluted share from $0.55 a year ago, a sharp 35% decline that underscored the magnitude of the turnaround challenge. The earnings compression reflects not only cost pressures but also segment-specific issues and the impact of field actions, limiting near-term equity upside.

Margins Squeezed by Costs and Tariffs

Adjusted gross margin slid 500 basis points to 36.8%, while adjusted operating margin fell 390 basis points to 11.0%, pointing to significant margin strain. Management cited timing of costs, tariffs, and higher manufacturing expenses including unfavorable absorption, all of which they expect to mitigate gradually as volumes recover and productivity actions ramp.

MPT and Infusion Systems Under Strain

The Medical Products & Therapies segment posted $1.3 billion in sales, down 2% organically, while Infusion Therapies & Technologies revenue declined 5% to $981 million. Performance was hurt by the ship and installation hold on the Novum LVP infusion pump and a difficult comparison against prior-year distributor inventory builds.

Novum LVP Field Actions Add Uncertainty

Novum LVP remains under a ship and installation hold, and Baxter acknowledged the possibility of customer returns or exchanges, though it did not quantify the potential impact. Management stressed that the combined pump portfolio, including Novum and Spectrum, accounts for less than 2% of sales, but the overhang continues to inject uncertainty into near-term results.

Pharma Hit by Supply Disruptions and Soft Demand

Injectables & Anesthesia sales declined 13%, with Injectables revenue at $301 million, reflecting supply constraints linked to a contract manufacturer disruption and weaker demand for inhaled anesthesia products. Baxter expects limited supply for certain injectable products into 2027, signaling that these headwinds could remain a drag for several years.

HST and Front Line Care Timing Issues

Healthcare Systems & Technology revenue fell 2% to $705 million, with Front Line Care down 4% to $270 million, largely due to the timing of government orders and large customer deals as well as planned portfolio exits. Management expects HST growth to be weighted toward the back half of the year as order timing normalizes and new solutions gain traction.

Tariffs and Inflation Continue to Bite

Baxter forecast a full-year tariff impact of about $80 million net of mitigation, representing a roughly $40 million year-over-year headwind that will weigh on 2026 results. Higher manufacturing costs and absorption pressure remain persistent challenges, although the company expects some relief as cost actions take hold and higher-cost inventory rolls off.

Nonoperating Expenses Weigh on Bottom Line

Net interest and other expense from continuing operations totaled $67 million in the quarter, and management guided to full-year nonoperating expenses of $280 million to $300 million. Higher interest expense and lower other income will continue to pressure net earnings, reinforcing the importance of debt reduction and cash flow improvement.

Muted Organic Growth and Cautious Near-Term Stance

Organic sales declined 1% in the quarter, and full-year guidance assumes roughly flat organic performance as management remains cautious about the near term. Ongoing uncertainty around Novum, persistent supply issues, and tougher first-half comparisons underpin this conservative stance, with hopes pinned on operational execution to drive a second-half inflection.

Outlook and Guidance Emphasize Back-Half Rebound

Baxter reiterated expectations for 2026 reported sales to be flat to up 1%, with about a 100-basis-point tailwind from foreign exchange and a modest headwind from a Vantive agreement, implying flat organic sales. Management expects Q2 to resemble Q1 in revenue and EPS, followed by a stronger second half driven by a roughly 500-basis-point swing in operating margins and back-half-weighted free cash flow, with deleveraging to about 3x net leverage remaining the primary financial goal.

Baxter’s earnings call painted a picture of a company in mid-turnaround, balancing real operational progress against tangible financial and operational headwinds. For investors, the story hinges on whether management can execute on productivity, resolve supply and field-action issues, and deliver the promised second-half margin recovery while steadily chipping away at leverage.